Human epidermal growth factor receptor 3 (HER3) blockade with U3-1287/AMG888 enhances the efficacy of radiation therapy in lung and head and neck carcinoma
Autor: | Chunrong, Li, Toni M, Brand, Mari, Iida, Shyhmin, Huang, Eric A, Armstrong, Albert, van der Kogel, Deric L, Wheeler |
---|---|
Rok vydání: | 2013 |
Předmět: |
Male
Lung Neoplasms Cell Death Receptor ErbB-3 Antibodies Neoplasm Cell Survival Antibodies Monoclonal Mice Nude Antibodies Monoclonal Humanized Antibodies Neutralizing Article body regions Gene Expression Regulation Neoplastic Mice Head and Neck Neoplasms Cell Line Tumor Enzyme Induction Animals Heterografts Humans skin and connective tissue diseases Broadly Neutralizing Antibodies Neoplasm Transplantation DNA Damage |
Zdroj: | Discovery medicine. 16(87) |
ISSN: | 1944-7930 |
Popis: | HER3 is a member of the epidermal growth factor receptor (EGFR) family of receptor tyrosine kinases. In the present study, we investigated the capacity of the HER3 blocking antibody, U3-1287/AMG888, to modulate the in vitro and in vivo radiation response of human squamous cell carcinomas of the lung and head and neck. We screened a battery of cell lines from these tumors for HER3 expression and demonstrated that all cell lines screened exhibited expression of HER3. Importantly, U3-1287/AMG888 treatment could block both basal HER3 activity and radiation induced HER3 activation. Proliferation assays indicated that HER3 blockade could decrease the proliferation of both HNSCC cell line SCC6 and NSCLC cell line H226. Further, we demonstrated that U3-1287/AMG888 can sensitize cells to radiation in clonogenic survival assays, in addition to increasing DNA damage as detected via λ-H2AX immunofluo-rescence. To determine if U3-1287/AMG888 could enhance radiation sensitivity in vivo we performed tumor growth delay experiments using SCC6, SCC1483, and H226 xenografts. The results of these experiments indicated that the combination of U3-1287/AMG888 and radiation could decrease tumor growth in studies using single or fractionated doses of radiation. Analysis of HER3 expression in tumor samples indicated that radiation treatment activated HER3 in vivo and that U3-1287/AMG888 could abrogate this activation. Immunohistochemistry analysis of SCC6 tumors treated with both U3-1287/AMG888 and a single dose of radiation demonstrated that various cell survival and proliferation markers could be reduced. Collectively our findings suggest that U3-1287/AMG888 in combination with radiation has an impact on cell and tumor growth by increasing DNA damage and cell death. These findings suggest that HER3 may play an important role in response to radiation therapy and blocking its activity in combination with radiation may be of therapeutic benefit in human tumors. |
Databáze: | OpenAIRE |
Externí odkaz: |